ACTengine® IMA203 Combined With mRNA-4203

Summary

This purpose of this clinical trial is to evaluate the safety, tolerability and anti-tumor activity of IMA203 in combination with different doses of mRNA-4203. The trial includes participants with previously treated unresectable or metastatic cutaneous melanoma (CM) or synovial sarcoma (SS).

Timeline

Start

2025-07-25

Primary completion

2029-08

Completion

2029-08

Drugs

Indications